Questions on the agenda for ACIP’s next meeting
-
By
-
Theresa Gaffney
-
February 26, 2026
-
Clinical Scorecard: Topics to be addressed at the upcoming ACIP meeting
At a Glance
| Category | Detail |
|---|
| Condition | Vaccine policy and Covid-19 vaccine-related injuries |
| Key Mechanisms | Advisory Committee on Immunization Practices (ACIP) recommendations on vaccine use and safety |
| Target Population | General population receiving vaccines, including infants and Covid-19 vaccine recipients |
| Care Setting | Public health and immunization policy settings |
Key Highlights
- ACIP meeting date shifted from February to March with potential votes on Covid-19 vaccine-related injuries.
- ACIP, now including vaccine skeptics, recommended blood testing after infant hepatitis B vaccination despite lack of supporting science.
- ACIP’s authority does not extend to vaccine injury compensation processes.
Guideline-Based Recommendations
Diagnosis
- No specific diagnostic recommendations provided.
Management
- ACIP can recommend changes to vaccine recommendations based on safety concerns.
Monitoring & Follow-up
- Recommendation for blood testing after first hepatitis B vaccine dose in infants was proposed but is currently on hold.
Risks
- Concerns about Covid-19 vaccine-related injuries are on the agenda for ACIP discussion.
- Recommendations outside ACIP’s purview may lack scientific support.
Patient & Prescribing Data
Infants receiving hepatitis B vaccine and individuals receiving Covid-19 vaccines
No evidence supports one dose of hepatitis B vaccine in infancy providing long-term protection; blood testing recommendation is controversial.
Clinical Best Practices
- Follow ACIP vaccine recommendations aligned with scientific evidence and regulatory authority.
- Avoid implementing recommendations outside ACIP’s established scope without supporting data.
- Monitor ongoing safety data for Covid-19 vaccines and adjust recommendations accordingly.
References
